Nanopublications LDF server

Matches in Nanopublications for { <http://purl.org/np/RAWwpHNaWTultFV9qB1FT3LuMep7eTZtjtEMB2OW5O-WU#association> ?p ?o ?g. }

• association type Statement assertion.
• association label "clarithromycin is a macrolide antimicrobial indicated for mild to moderate infections caused by designated susceptible bacteria in the following acute bacterial exacerbation of chronic bronchitis in adults 1 1 acute maxillary sinusitis 1 2 community acquired pneumonia 1 3 pharyngitis tonsillitis 1 4 uncomplicated skin and skin structure infections 1 5 acute otitis media in pediatric patients 1 6 treatment and prophylaxis of disseminated mycobacterial infections 1 7 helicobacter pylori 1 8 limitations of use clarithromycin extended release tablets are indicated only for acute bacterial exacerbation of chronic bronchitis acute maxillary sinusitis and community acquired pneumonia in adults 1 9 to reduce the development of drug resistant bacteria and maintain the effectiveness of clarithromycin and other antibacterial drugs clarithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria 1 9 clarithromycin tablets clarithromycin for oral suspension and clarithromycin extended release tablets are indicated in adults for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae haemophilus parainfluenzae moraxella catarrhalis streptococcus pneumoniae see indications and usage 1 9 clarithromycin tablets clarithromycin for oral suspension and clarithromycin extended release tablets in adults are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae moraxella catarrhalis streptococcus pneumoniae see indications and usage 1 9 clarithromycin tablets clarithromycin for oral suspension and clarithromycin extended release tablets are indicated see indications and usage 1 9 haemophilus influenzae haemophilus parainfluenzae moraxella catarrhalis mycoplasma pneumoniae streptococcus pneumoniae chlamydophila pneumoniae clarithromycin tablets and clarithromycin for oral suspension are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to streptococcus pyogenes clarithromycin tablets and clarithromycin for oral suspension are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to staphylococcus aureus streptococcus pyogenes clarithromycin tablets and clarithromycin for oral suspension are indicated in pediatric patients for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae moraxella catarrhalis streptococcus pneumoniae see clinical studies 14 2 clarithromycin tablets and clarithromycin for oral suspension are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to mycobacterium avium mycobacterium intracellulare see clinical studies 14 1 clarithromycin tablets are given in combination with other drugs in adults as described below to eradicate h pylori h pylori see clinical studies 14 3 clarithromycin tablets in combination with amoxicillin and prevacid lansoprazole or prilosec omeprazole delayed release capsules as triple therapy are indicated for the treatment of patients with h pylori h pylori clarithromycin tablets in combination with prilosec omeprazole capsules are indicated for the treatment of patients with an active duodenal ulcer associated with h pylori clarithromycin extended release tablets are indicated only for acute maxillary sinusitis acute bacterial exacerbation of chronic bronchitis and community acquired pneumonia in adults the efficacy and safety of clarithromycin extended release tablets in treating other infections for which clarithromycin tablets and clarithromycin for oral suspension are approved have not been established there is resistance to macrolides in certain bacterial infections caused by streptococcus pneumoniae staphylococcus aureus to reduce the development of drug resistant bacteria and maintain the effectiveness of clarithromycin and other antibacterial drugs clarithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy" assertion.
• association object DOID_2050 assertion.
• association predicate treats assertion.
• association subject drugbank:DB01211 assertion.
• association association_type ChemicalToDiseaseOrPhenotypicFeatureAssociation assertion.
• association provided_by NeuroDKG assertion.
• association relation TreatmentIndication assertion.